BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 34452551)

  • 1. Immune Dysfunction as Measured by the Systemic Immune-Inflammation Index is Associated with the Sub-Type of Minimal Residual Disease and Outcome in Stage II Colon Cancer Treated with Surgery alone.
    Murray NP; Villalon R; Orrego S; Guzman E
    Asian Pac J Cancer Prev; 2021 Aug; 22(8):2391-2397. PubMed ID: 34452551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The association of the neutrophil-lymphocyte ratio with the presence of minimal residual disease and outcome in patients with Stage II colon cancer treated with surgery alone.
    Murray NP; Villalon R; Orrego S; Guzman E
    Colorectal Dis; 2021 Apr; 23(4):805-813. PubMed ID: 33169474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.
    Murray NP; Villalon R; Hartmann D; Rodriguez PM; Aedo S
    Asian Pac J Cancer Prev; 2022 Feb; 23(2):591-599. PubMed ID: 35225472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative prognostic nutritional index and systemic immune-inflammation index predict survival outcomes in osteosarcoma: A comparison between young and elderly patients.
    Ma C; Yu R; Li J; Guo J; Xu J; Wang X; Liu P
    J Surg Oncol; 2022 Mar; 125(4):754-765. PubMed ID: 34811745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative Surgery.
    Murray NP; Villalon R; Aedo S; Hartmann D; Rodriguez MP
    Asian Pac J Cancer Prev; 2023 Oct; 24(10):3373-3379. PubMed ID: 37898840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
    Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
    Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.
    Murray NP; Villalon R; Hartmann D; Rodriguez MP; Aedo S
    Colorectal Dis; 2021 Nov; 23(11):2879-2893. PubMed ID: 34473913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of systemic inflammation biomarkers on the survival outcomes of cervical cancer patients.
    Holub K; Biete A
    Clin Transl Oncol; 2019 Jul; 21(7):836-844. PubMed ID: 30470994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
    Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
    [No Abstract]   [Full Text] [Related]  

  • 11. Subtypes of minimal residual disease and outcome for stage II colon cancer treated by surgery alone.
    Murray NP; Aedo S; Villalon R; Albarran V; Orrego S; Guzman E
    Ecancermedicalscience; 2020; 14():1119. PubMed ID: 33209110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
    Yan X; Li G
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Circulating prostate cells and bone marrow micro-metastasis and not treatment modality determine the risk and time to biochemical failure in low risk prostate cancer.].
    Murray NP; Aedo S; Fuentealba C; Salazar A; Reyes E; Lopez MA; Minzer S
    Arch Esp Urol; 2019 Dec; 72(10):1000-1009. PubMed ID: 31823848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of the C-Reactive Protein/Albumin Ratio and Systemic Immune-Inflammation Index for Patients With Colorectal Liver Metastasis Undergoing Curative Resection.
    Deng Y; Zhao Y; Qin J; Huang X; Wu R; Zhou C; Pan Z
    Pathol Oncol Res; 2021; 27():633480. PubMed ID: 34257601
    [No Abstract]   [Full Text] [Related]  

  • 15. The predictive value of systemic immune inflammation index for postoperative survival of gallbladder carcinoma patients.
    Chen H; Huang Z; Sun B; Wang A; Wang Y; Shi H; Zheng T; Li T; Huang M; Fu W
    J Surg Oncol; 2021 Jul; 124(1):59-66. PubMed ID: 33765331
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-treatment systemic immune-inflammation index is a useful prognostic indicator in patients with breast cancer undergoing neoadjuvant chemotherapy.
    Chen L; Kong X; Wang Z; Wang X; Fang Y; Wang J
    J Cell Mol Med; 2020 Mar; 24(5):2993-3021. PubMed ID: 31989747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammation-based indexes and clinicopathologic features are strong predictive values of preoperative circulating tumor cell detection in gastric cancer patients.
    Zheng L; Zou K; Yang C; Chen F; Guo T; Xiong B
    Clin Transl Oncol; 2017 Sep; 19(9):1125-1132. PubMed ID: 28315180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
    Rice SJ; Belani CP
    PLoS One; 2021; 16(12):e0260988. PubMed ID: 34855926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic immune-inflammation index for predicting prognosis of colorectal cancer.
    Chen JH; Zhai ET; Yuan YJ; Wu KM; Xu JB; Peng JJ; Chen CQ; He YL; Cai SR
    World J Gastroenterol; 2017 Sep; 23(34):6261-6272. PubMed ID: 28974892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.